WO2007059202A3 - Derives de pyrazolyluree utilisables dans le traitement du cancer - Google Patents

Derives de pyrazolyluree utilisables dans le traitement du cancer Download PDF

Info

Publication number
WO2007059202A3
WO2007059202A3 PCT/US2006/044322 US2006044322W WO2007059202A3 WO 2007059202 A3 WO2007059202 A3 WO 2007059202A3 US 2006044322 W US2006044322 W US 2006044322W WO 2007059202 A3 WO2007059202 A3 WO 2007059202A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
urea derivatives
derivatives useful
pyrazolyl urea
Prior art date
Application number
PCT/US2006/044322
Other languages
English (en)
Other versions
WO2007059202A2 (fr
Inventor
Louis-David Cantin
Roger Smith
Zhi Chen
Holia N Hatoum-Mokdad
Eric Mull
Original Assignee
Bayer Pharmaceuticals Corp
Louis-David Cantin
Roger Smith
Zhi Chen
Holia N Hatoum-Mokdad
Eric Mull
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Louis-David Cantin, Roger Smith, Zhi Chen, Holia N Hatoum-Mokdad, Eric Mull filed Critical Bayer Pharmaceuticals Corp
Priority to CA002629468A priority Critical patent/CA2629468A1/fr
Priority to EP06837652A priority patent/EP1960394A2/fr
Publication of WO2007059202A2 publication Critical patent/WO2007059202A2/fr
Publication of WO2007059202A3 publication Critical patent/WO2007059202A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La présente invention concerne des composés de pyrazole urée, des compositions pharmaceutiques qui les contiennent et des procédés de traitement du cancer qui les utilisent.
PCT/US2006/044322 2005-11-15 2006-11-15 Derives de pyrazolyluree utilisables dans le traitement du cancer WO2007059202A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002629468A CA2629468A1 (fr) 2005-11-15 2006-11-15 Derives de pyrazolyluree utilisables dans le traitement du cancer
EP06837652A EP1960394A2 (fr) 2005-11-15 2006-11-15 Derives de pyrazolyluree utilisables dans le traitement du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73640005P 2005-11-15 2005-11-15
US60/736,400 2005-11-15

Publications (2)

Publication Number Publication Date
WO2007059202A2 WO2007059202A2 (fr) 2007-05-24
WO2007059202A3 true WO2007059202A3 (fr) 2007-08-09

Family

ID=38016517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/044322 WO2007059202A2 (fr) 2005-11-15 2006-11-15 Derives de pyrazolyluree utilisables dans le traitement du cancer

Country Status (3)

Country Link
EP (1) EP1960394A2 (fr)
CA (1) CA2629468A1 (fr)
WO (1) WO2007059202A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006029795A1 (de) * 2006-06-27 2008-01-03 Schebo Biotech Ag Neue Harnstoff-Derivate und deren Verwendungen
DK2229391T3 (da) 2007-12-19 2014-10-13 Cancer Res Inst Royal Pyrido[2,3-B]pyrazin-8-substituerede forbindelser og deres anvendelse
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
PE20110598A1 (es) 2008-10-02 2011-08-31 Respivert Ltd Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
US8299073B2 (en) 2008-12-11 2012-10-30 Respivert Ltd. P38 MAP kinase inhibitors
JP2012516843A (ja) * 2009-02-02 2012-07-26 インドコ レメディーズ リミテッド ニトロピリジン誘導体の調製方法
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
CN102906090B (zh) 2010-02-01 2015-06-24 癌症研究技术有限公司 1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用
WO2012003338A1 (fr) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet
KR101960555B1 (ko) 2011-05-13 2019-03-20 어레이 바이오파마 인크. Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078408A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés d'hétéroaryle urée, thiourée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
DK2922844T3 (en) 2012-11-13 2018-03-05 Array Biopharma Inc N-PYRROLIDINYL, N'-PYRAZOLYL-URINE, THIOURINE, GUANIDINE AND CYANOGUANIDE COMPOUNDS AS TRKA-KINASE INHIBITORS
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078331A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-(arylalkyle)-n'-pyrazolyle-urée, de thiourée, de guanidine et de cyanoguanidine en tant qu'inhibiteurs de la kinase trka
WO2014078322A1 (fr) * 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de thiazolyl-urée, oxazolyl-urée, thio-urée, guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
WO2014078325A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-aryle monocycliques, n'-pyrazolyl-urée, thiourée, guanidine et cyanoguanidine utiles comme inhibiteurs de trka kinase
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
MX366761B (es) * 2012-11-13 2019-07-23 Array Biopharma Inc Compuestos bíciclicos de urea, tiourea, guanidina y cianoguanidina útiles para el tratamiento del dolor.
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
MA40434B1 (fr) 2014-05-15 2019-09-30 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka
EP3229836B1 (fr) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Anticoprs monoclonaux contre 'axl'
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
CN107056653B (zh) * 2017-06-09 2019-07-09 丽珠医药集团股份有限公司 布南色林中间体对氟苯甲酰乙腈的合成方法
US20230089368A1 (en) 2019-07-19 2023-03-23 Anagenesis Biotechnologies S.A.S. Polyaromatic urea derivatives and their use in the treatment of muscle diseases
EP4029501A1 (fr) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combinaison de dérivés polyaromatiques de l'urée et d'inhibiteur glucocorticoïde ou hdac pour le traitement de maladies ou d'affections associées aux cellules musculaires et/ou aux cellules satellites

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032455A1 (fr) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition de raf kinase a l'aide d'urees heterocycliques aryle et heteroaryle substituees
WO1999032106A1 (fr) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition de raf kinase au moyen d'urees heterocycliques substituees
WO2005110994A2 (fr) * 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Derives de pyrazolyl uree substitues utiles dans le traitement du cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032455A1 (fr) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition de raf kinase a l'aide d'urees heterocycliques aryle et heteroaryle substituees
WO1999032106A1 (fr) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition de raf kinase au moyen d'urees heterocycliques substituees
WO2005110994A2 (fr) * 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Derives de pyrazolyl uree substitues utiles dans le traitement du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JACQUES DUMAS, HOLIA HATOUM-MOKDAD, ROBERT N. SIBLEY, ROGER A. SMITH, WILLIAM J. SCOTT, UDAY KHIRE, WENDY LEE ET AL.: "Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 1559 - 1562, XP002434053 *

Also Published As

Publication number Publication date
EP1960394A2 (fr) 2008-08-27
CA2629468A1 (fr) 2007-05-24
WO2007059202A2 (fr) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2007059202A3 (fr) Derives de pyrazolyluree utilisables dans le traitement du cancer
WO2007064872A3 (fr) Composes de l'uree utilises dans le traitement du cancer
WO2005110994A3 (fr) Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
WO2006102504A3 (fr) Combinaisons destinees au traitement de cancer
WO2007011962A3 (fr) Traitement du cancer
WO2008098104A8 (fr) Inhibiteurs de l'activité de akt
WO2007059008A3 (fr) Indenoisoquinolines n-substituees et leur synthese
WO2005048948A3 (fr) Derives d'uree en tant que modulateurs de la kinase
WO2007076423A3 (fr) INHIBITEURS D’ACTIVITE Akt
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
WO2006086562A3 (fr) Derives de phenylazetidinone
WO2007067781A3 (fr) Inhibiteurs de proteines kinases
WO2006083971A3 (fr) Anticorps dr5 et utilisations de ceux-ci
WO2007064945A3 (fr) Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies
WO2008030883A3 (fr) Traitement du cancer
IL191938A (en) The ovarian heterocellular compounds, pharmaceuticals containing them, and the ovarian heterocellular compounds for cancer treatment
WO2008021368A3 (fr) Compositions et méthodes de neuroprotection
IL199151A (en) Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
WO2007079164A3 (fr) Inhibiteurs de protéines kinases
TNSN07322A1 (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2006004833A3 (fr) Inhibiteurs de kinase a base de pyrrolotriazine
IL185484A0 (en) Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2007120333A3 (fr) Inhibiteurs de kinase tétracycliques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2629468

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008541303

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006837652

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06837652

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: JP